Management of the Adult Onset Diabetic with Sulfonylurea Drug Failure (Q36240017)

13 August 2017

1 reference

title

Management of the adult onset diabetic with sulfonylurea drug failure (English)

1 reference

13 August 2017

Management of the Adult Onset Diabetic with Sulfonylurea Drug Failure (English)

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

15 October 2022

S. Genuth

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1612070

15 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1612070

15 October 2022

publication date

1 June 1992

1 reference

full work available at URL

13 August 2017

https://api.elsevier.com/content/article/PII:S0889852918302214?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

https://api.elsevier.com/content/article/PII:S0889852918302214?httpAccept=text/plain

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Endocrinology and Metabolism Clinics of North America

15 October 2022

published in

1 reference

13 August 2017

1 reference

13 August 2017

1 reference

13 August 2017

page(s)

351-370

1 reference

Management of non-insulin-dependent diabetes mellitus in Europe: a concensus view

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Combination insulin-sulfonylurea therapy in type II diabetes mellitus.

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Combination therapy with insulin and sulfonylureas for type II diabetes

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Comparison of the absorption and biological activity of NPH human insulin (recombinant DNA) and NPH porcine insulin injected subcutaneously in type II diabetic patients

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Insulin therapy in the elderly type 2 diabetic patient

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

15 October 2022

Insulin Pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Basal-rate intravenous insulin infusion compared to conventional insulin treatment in patients with type II diabetes. A prospective crossover trial

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Monomeric insulins and their experimental and clinical implications

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Insulin-glyburide combination therapy for non-insulin-dependent diabetes mellitus: a long-term double-blind, placebo-controlled trial

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Severe hypoglycemia in diabetic patients: frequency, causes, prevention

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Diabetes Control and Complications Trial (DCCT): results of feasibility study. The DCCT Research Group

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Feasibility of adjustment of insulin dose by insulin-requiring type II diabetic patients.

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Improvement in in vitro insulin action after one month of insulin therapy in obese noninsulin-dependent diabetics. Measurements of glucose transport and metabolism, insulin binding, and lipolysis in isolated adipocytes

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Treatment of NIDDM with insulin agonists or substitutes

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture.

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Plasma Insulin and Glucose Profiles in Normal, Obese, and Diabetic Persons

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Control of hyperglycemia in adult diabetics by pulsed insulin delivery

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Supplemented fasting in the treatment of obesity and diabetes

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

15 October 2022

Oral hypoglycemic agents

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

One month's insulin treatment of type II diabetes: the early and medium-term effects following insulin withdrawal

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes.

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Insulin treatment of non-insulin-dependent diabetes mellitus

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Improvement of insulin secretion but not insulin resistance after short term control of plasma glucose in obese type II diabetics.

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

A Comparison of the Relative Effects of Obesity and Non-insulin-dependent Diabetes Mellitus on In Vivo Insulin-stimulated Glucose Utilization

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycaemic agents

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Islet dysfunction in non-insulin-dependent diabetes mellitus

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Effects of Combination Therapy With Glyburide and Insulin on Serum Lipid Levels in NIDDM Patients With Secondary Sulfonylurea Failure

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Combination insulin-sulfonylurea therapy

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Glyburide and glipizide in treatment of diabetic patients with secondary failures to tolazamide or chlorpropamide

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Effects of combined insulin-sulfonylurea therapy in type II patients

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Does day-long absolute hypoinsulinemia characterize the patient with non-insulin-dependent diabetes mellitus?

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

When to start an NIDDM patient on insulin. Which insulin programme could be recommended?

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Secondary failure of oral antidiabetic and dietetic therapy in non-insulin-dependent diabetes mellitus. Remission through short sessions of continuous intravenous insulin infusion.

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Metabolite-regulated ATP-sensitive K+ channel in human pancreatic islet cells

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

The endogenous insulin secretion was suppressed during insulin therapy in NIDDM patients

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Five-year follow-up study on plasma insulin levels in newly diagnosed NIDDM patients and nondiabetic subjects

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Reduced Solubility of Short-Acting Soluble Insulins when Mixed with Longer-Acting Insulins

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Comparison of Basal and Prandial Insulin Therapy in Patients with Secondary Failure of Sulphonylurea Therapy

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Insulin plus a Sulfonylurea Agent for Treating Type 2 Diabetes

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

The combined use of insulin and sulfonylurea therapy in patients with non-insulin dependent diabetes mellitus

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

15 October 2022

Evening insulin strategy

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Effect of insulin and glucose on feeding behavior.

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Insulin therapy in maturity-onset diabetes

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Insulin treatment reverses the insulin resistance of type II diabetes mellitus.

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Effects of 8-wk alpha-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Effects of short-term insulin therapy upon therapeutic response to glipizide

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Comparison of high fibre diets, basal insulin supplements, and flexible insulin treatment for non-insulin dependent (type II) diabetics poorly controlled with sulphonylureas

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Direct Effect of Insulin on Secretion of Insulin, Glucagon, Gastric Inhibitory Polypeptide, and Gastrin during Maintenance of Normoglycemia*

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic patients

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

When to use insulin in the maturity onset diabetic

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Effect of acarbose on the 24-hour blood glucose profile and pattern of carbohydrate absorption

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

The combined treatment with insulin and sulfonylurea in non-insulin-dependent diabetic patients with secondary failure. Rationale and guidelines.

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Insulin increases body fat despite control of food intake and physical activity

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Low-dose bedtime NPH insulin in treatment of secondary failure to glyburide

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Insulin use in NIDDM. Rationale based on pathophysiology of disease

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Role of metformin in treatment of diabetes mellitus

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

A randomized crossover study of sulphonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy

15 October 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Effects of body composition on insulin sensitivity

15 October 2022

102

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Influence of body composition on insulin clearance

15 October 2022

103

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure

15 October 2022

104

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

Hypoglycemia--mechanisms and prevention in NIDDM treatment with insulin

15 October 2022

105

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

The physiologic replacement of insulin. An elusive goal

15 October 2022

107

1 reference

https://api.crossref.org/works/10.1016/S0889-8529(18)30221-4

15 October 2022

Identifiers

1 reference